B.L.Kashyap & Sons Ltd
BLKASHYAPB.L.Kashyap & Sons Ltd's price has outrun its earnings. −27.5% in a year against EPS −94.3% — the market is paying now for delivery later.
The sharpest disagreement: the price moved −27.5% in a year while annual EPS moved −94.3% — the difference is re-rating, and re-rating has to be repaid with earnings.
The price is building a base (7 weeks in) while the P/E sits at the 76th percentile of its own 9-year range. Underneath, the last four quarters read improving, and 329% of the last 3 years' profit arrived as cash. What settles it: whether earnings grow into a price that has already moved.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
B.L.Kashyap & Sons Ltd trades at ₹54.5, building a base and 7 weeks into that stage. That is −1.7% against its own 200-day average. It sits at 34% of a 52-week range of ₹47 to ₹70. On relative strength it is currently behind the NIFTY 500 on a trailing-13-week view (6 weeks and counting).
Today the stock is building a base — week 7 of stage 1, confirmed. At ₹54.5 it trades −1.7% versus its 200-day average and sits at 34% of its 52-week range (₹47–₹70).
Against the market, two honest reads. Cumulative: over the last 10.4 years the stock moved +272% while the NIFTY 500 moved +276% — behind the index over the full window. Recent form: on a trailing-13-week view the stock is currently behind (6 weeks and counting; last ahead the week of 2026-06-25) — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
B.L.Kashyap & Sons Ltd trades at 90.2× P/E, at the pricey end of its own range (76th percentile). Its long-run median P/E is 33.4×, measured across 8.9 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 90.2× is at the pricey end of its own range (76th percentile), against a long-run median of 33.4× measured over 8.9 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
🚨 Why the multiple sits where it does: over the past year annual EPS moved −94.3% against a −27.5% price move — the price outran earnings, pushing the multiple UP its own range.
The price move, decomposed: over 3y, of the +9.1%/yr price move, ~−34.7%/yr came from earnings growth and ~+43.8 pp from the multiple (expanding). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is full against its own past, so the story rests on the earnings line underneath it, not the multiple.
A quarterly PEG curve, which only the second data source carries, is not drawn on this page: its two data sources do not share enough overlapping reported history to be compared. A figure nobody could check is not used to price growth — the gap is a decision, not missing data.
Stage: Mixed Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
B.L.Kashyap & Sons Ltd reads as mixed on its fundamental arc. Mixed — no clean majority across the growth curves, ROCE holding at 13.0% — the per-curve reads carry the story. The read is built from 10 quarters across 3 curves, on partial evidence.
Why it matters: when the curves disagree, the per-curve reads above matter more than any single verdict.
One or more growth curves carry a base-effect spike — a large year-on-year move off a near-zero or loss-making comparable quarter. Those spikes are capped before the classifier reads the trajectory, and shown pinned on the chart, so a single distorted quarter does not drive the stage call.
Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.
A partial read: at least one curve is short, or the returns curve is not the computed quarterly series — hold the stage word a little more loosely.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +19.5% | +7.5% | +12.6% | +4.8% |
| Profit | −92.6% | −55.0% | — | — |
| EPS | −94.3% | −58.5% | — | — |
| Share price | −27.5% | +9.1% | +16.6% | +10.8% |
4-Factor Sector Score
46.2/100 — rank 8 of 13 in Construction - Civil/Turnkey · 62% evidence confidence
B.L.Kashyap & Sons Ltd scores 46.2 out of 100 against the 13 companies it is compared with in Construction - Civil/Turnkey, ranking 8. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
The four contributions add to the total exactly: 22.4 + 8.6 + 9 + 6.2 = 46.2. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
B.L.Kashyap & Sons Ltd reported ₹364 Cr of revenue in the Mar 26 quarter, +23.8% year on year. That is the 3rd straight quarter of year-on-year growth. Over 10 years it has compounded at 4.8% a year. The last full year, FY26, came in at ₹1,379 Cr. The last four reported quarters add to ₹1,379 Cr.
FY26 revenue came in at ₹1,379 Cr (+19.5% on the year), capping 10 years at 4.8% compound. The latest quarter (Mar 26) printed ₹364 Cr, +23.8% year on year — the 3rd consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +21.7% growth against the decade's 4.8% — the current year is running faster than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +19.6% over the last 4 quarters against +5.2%/yr over the last 8 — accelerating; TTM profit −96.3% vs −86.3%/yr — rolling over.
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
B.L.Kashyap & Sons Ltd's operating margin is 7.0% in the Mar 26 quarter, +4.5 percentage points against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 2.2% to 10.0%. The current quarter sits inside that band.
The latest quarter's operating margin is 7.0%, +4.5 pp against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 2.2%–10.0%.
Why the margin moved: operating margin went +4.9 pp year on year while gross margin went +5.0 pp — the gain came mostly from the gross line: input costs and pricing.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
B.L.Kashyap & Sons Ltd posted a net loss of ₹13.0 Cr in the Mar 26 quarter. Full-year FY26 profit was ₹2.0 Cr. That loss is 3.6% of the quarter's revenue. The same quarter a year earlier lost ₹3.0 Cr. 3 of the last 12 reported quarters were loss-making.
Mar 26 profit was ₹−13.0 Cr, null year on year. On the full year, FY26 printed ₹2.0 Cr (−92.6%).
Pace comparison, last four quarters: profit +285.0% vs revenue +21.7%. Profit is growing faster than sales — fixed costs are being spread over a bigger base, and each extra rupee of revenue drops more to the bottom line.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 329% of B.L.Kashyap & Sons Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY26 that was ₹115 Cr of operating cash against ₹2.0 Cr of profit. After ₹56.0 Cr of capital spending, ₹59.0 Cr was left as free cash.
FY26: operating cash of ₹115 Cr against reported profit of ₹2.0 Cr, leaving free cash of ₹59.0 Cr after ₹56.0 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 329% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why conversion sits at 329%: the cash cycle tightened 114 days between FY21 and FY26 — cash that used to wait in the cycle now reaches the bank sooner.
Router verdict: the bigger cash user is investment — capital spending ran 3.7× depreciation over three years, so the next section's job is to check what that build-out is buying.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
B.L.Kashyap & Sons Ltd's cash conversion cycle runs 96 days in FY26, down from 210 days in FY21. Capital spending ran ₹137 Cr over the last 3 years. At FY26 sales of ₹1,379 Cr each day of that cycle holds about ₹3.8 Cr, so roughly ₹363 Cr sits inside the business at any moment.
FY26: debtors at 115 days, inventory at 65 days — roughly 2.1 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 96 days, tighter than FY21's 210.
The full loop: cash goes out to suppliers and production on day 0; stock waits 65 days to sell; customers pay about 115 days after that; and suppliers themselves are paid at 84 days — netting out to the 96-day cycle.
In money terms: at FY26 sales of ₹1,379 Cr, each day of the cycle holds about ₹3.8 Cr — so the 96-day loop keeps roughly ₹363 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹137 Cr over the last 3 fiscal years against ₹37.0 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹0.0 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.⚠ unverified
B.L.Kashyap & Sons Ltd earns a ROCE of 13% in FY26. That is up from a trough of 0% in FY15. Return on invested capital clears the cost of that capital by −11.4 percentage points, so growth here is not yet paying for the capital it uses. The wiring behind it is 0.1% net margin on 0.83× asset turns.
FY26 ROCE is 13%, recovered from a FY15 trough of 0% — the full ladder below shows the fall and the climb, undoctored.
🚨 Why the return is what it is — the wiring (FY26): 0.1% net margin × 0.83× asset turns × 3.15× balance-sheet leverage ≈ 0.3% on equity. Margin does its share; leverage is a meaningful part of the equation.
The capstone test — ROIC − WACC: 0.6% − 12.0% = a −11.4 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. Negative — growth at these returns destroys value until the returns recover.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.⚠ unverified
B.L.Kashyap & Sons Ltd carries total debt of ₹299 Cr against shareholder equity of ₹527 Cr as of Mar 26, a debt-to-equity of 0.57. On the annual view that ratio went from 0.90 in FY22 to 0.57 in FY26. Read the returns elsewhere on this page with that leverage in mind.
Mar 26: total debt of ₹299 Cr against shareholder equity of ₹527 Cr — a debt-to-equity of 0.57. On the annual view, debt-to-equity went from 0.90 (FY22) to 0.57 (FY26). Read the returns on this page with that leverage in mind.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
Foreign institutions cut 1.4 points of B.L.Kashyap & Sons Ltd over 8 quarters, the biggest move on the register. That takes foreign institutions to 0.3% of the company. Domestic institutions moved +0.2 points over the same window, to 0.2%. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — Foreign institutions: −1.4 points over 8 quarters to 0.3%; Domestic institutions: +0.2 points over 8 quarters to 0.2%; Promoters: +0.1 points over 8 quarters to 61.7%.
🚨 Why the register moved: foreign institutions drove it (−1.4 points) — distribution into the market’s bid.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
B.L.Kashyap & Sons Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.
The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Effwa Infra & Research LtdEFFWA | 66.7/100Thin evidence · provisional56% evidence | LEADER | 17.0/35 Revenue — · PAT — · OPM change -2 pp 26% evidence | 19.7/25 ROCE 29.3% · OPM 16% 95% evidence | 10.0/20 P/E 30× · PEG — 15% evidence | 20.0/20 RS sector 36.5% · RS bench 47.4% · 1Y 62%12 of 12 weeks ahead 100% evidence |
| Exact sum: 17 + 19.7 + 10 + 20 = 66.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 2SRM Contractors LtdSRM | 65.1/100Favorable setup76% evidence | FADING | 27.0/35 Revenue 94.1% · PAT 100% · OPM change 2 pp 83% evidence | 19.4/25 ROCE 37.1% · OPM 17% 95% evidence | 11.0/20 P/E 10.2× · PEG — 15% evidence | 7.7/20 RS sector -9.8% · RS bench -1.9% · 1Y 5.7%8 of 12 weeks ahead 100% evidence |
| Exact sum: 27 + 19.4 + 11 + 7.7 = 65.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 3Brahmaputra Infrastructure Ltd535693 | 62.2/100Mixed-positive evidence63% evidence | 22.2/35 Revenue 50.4% · PAT 100% · OPM change -8 pp 83% evidence | 14.9/25 ROCE 18.2% · OPM 22% 76% evidence | 13.2/20 P/E 8.1× · PEG — 50% evidence | 11.9/20 RS sector — · RS bench 23.8% · 1Y — 25% evidence | |
| Exact sum: 22.2 + 14.9 + 13.2 + 11.9 = 62.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 4Gayatri Projects LtdGAYAPROJ | 60.5/100Mixed-positive evidence77% evidence | LEADER | 28.0/35 Revenue 88.2% · PAT 100% · OPM change 28 pp 83% evidence | 4.3/25 ROCE 7% · OPM 9% 95% evidence | 12.2/20 P/E 10.4× · PEG — 50% evidence | 16.0/20 RS sector 12.3% · RS bench 39.6% · 1Y 135.1%11 of 12 weeks ahead 70% evidence |
| Exact sum: 28 + 4.3 + 12.2 + 16 = 60.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 5Ceigall India LtdCEIGALL | 53.6/100Mixed-positive evidence71% evidence | FADING | 15.0/35 Revenue 17.1% · PAT 7.3% · OPM change 3 pp 83% evidence | 14.2/25 ROCE 17.3% · OPM 16% 76% evidence | 10.2/20 P/E 19.1× · PEG — 15% evidence | 14.2/20 RS sector 7% · RS bench 15.8% · 1Y 30%10 of 12 weeks ahead 100% evidence |
| Exact sum: 15 + 14.2 + 10.2 + 14.2 = 53.6 · Decision use: Price leads the evidence: RS versus the benchmark is 15.8%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 6Denta Water & Infra Solutions LtdDENTA | 48.4/100Mixed-negative evidence70% evidence | TURNING | 14.8/35 Revenue 23.2% · PAT 15.2% · OPM change -11.2 pp 83% evidence | 15.1/25 ROCE 18.8% · OPM 19.3% 95% evidence | 10.5/20 P/E 15.5× · PEG — 15% evidence | 8.0/20 RS sector -26.8% · RS bench 7.3% · 1Y 7.3%6 of 10 weeks ahead 70% evidence |
| Exact sum: 14.8 + 15.1 + 10.5 + 8 = 48.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 7Sathlokhar Synergys E&C Global LtdSSEGL | 48.4/100Thin evidence · provisional57% evidence | ASLEEP | 16.8/35 Revenue — · PAT — · OPM change 4 pp 45% evidence | 16.5/25 ROCE 37.1% · OPM 15% 95% evidence | 11.5/20 P/E 8.1× · PEG — 15% evidence | 3.6/20 RS sector -31.4% · RS bench -24% · 1Y -19.4%0 of 10 weeks ahead 70% evidence |
| Exact sum: 16.8 + 16.5 + 11.5 + 3.6 = 48.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 8B.L.Kashyap & Sons Ltdthis pageBLKASHYAP | 46.2/100Mixed-negative evidence62% evidence | ASLEEP | 22.4/35 Revenue 19.6% · PAT -80% · OPM change 4.5 pp 62% evidence | 8.6/25 ROCE 13% · OPM 7% 95% evidence | 9.0/20 P/E 90.2× · PEG — 15% evidence | 6.2/20 RS sector -22.6% · RS bench -3.2% · 1Y -23.8%4 of 10 weeks ahead 70% evidence |
| Exact sum: 22.4 + 8.6 + 9 + 6.2 = 46.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 9A B Infrabuild LtdABINFRA | 43.9/100Mixed-negative evidence70% evidence | ASLEEP | 14.6/35 Revenue 23.1% · PAT 20% · OPM change -3.1 pp 83% evidence | 11.3/25 ROCE 16.1% · OPM 14.4% 95% evidence | 9.6/20 P/E 33.2× · PEG — 15% evidence | 8.4/20 RS sector -0.4% · RS bench -40.9% · 1Y -44.2%0 of 10 weeks ahead 70% evidence |
| Exact sum: 14.6 + 11.3 + 9.6 + 8.4 = 43.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 10Interise TrustINTERISE | 42.8/100Thin evidence · provisional51% evidence | 15.8/35 Revenue 2.1% · PAT 100% · OPM change -5 pp 83% evidence | 8.5/25 ROCE 10.8% · OPM 62% 76% evidence | 8.5/20 P/E 271× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y — 0% evidence | |
| Exact sum: 15.8 + 8.5 + 8.5 + 10 = 42.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 11Afcons Infrastructure LtdAFCONS | 31.5/100Adverse evidence83% evidence | ASLEEP | 6.2/35 Revenue -4.8% · PAT -48.7% · OPM change -7.4 pp 88% evidence | 7.1/25 ROCE 13.9% · OPM 1.6% 100% evidence | 14.2/20 P/E 33.2× · PEG 0.82 65% evidence | 4.0/20 RS sector -30% · RS bench -25.9% · 1Y -34.5%3 of 10 weeks ahead 70% evidence |
| Exact sum: 6.2 + 7.1 + 14.2 + 4 = 31.5 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 12HRS Aluglaze Ltd544656 | 53.6/100Thin evidence · provisional18% evidence | 17.9/35 Revenue — · PAT — · OPM change — 3% evidence | 17.0/25 ROCE 20.2% · OPM 32% 57% evidence | 8.7/20 P/E 105× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —2 of 2 weeks ahead to 2026-03-29 0% evidence | |
| Exact sum: 17.9 + 17 + 8.7 + 10 = 53.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 13GHV Infra Projects Ltd505504 | 51.4/100Thin evidence · provisional35% evidence | BASING | 17.9/35 Revenue — · PAT — · OPM change 0 pp 14% evidence | 14.6/25 ROCE — · OPM 18% 30% evidence | 9.3/20 P/E 43.5× · PEG — 15% evidence | 9.6/20 RS sector -5.8% · RS bench 3.1% · 1Y 5.5%0 of 12 weeks ahead 100% evidence |
| Exact sum: 17.9 + 14.6 + 9.3 + 9.6 = 51.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is B.L.Kashyap & Sons Ltd's share price today?
B.L.Kashyap & Sons Ltd trades at ₹54.5, −27.5% over the past year. The company is valued at ₹1,228 Cr. The stock sits at 34% of its 52-week range of ₹47–₹70, −1.7% versus its 200-day average. On the tape, the price is building a base, 7 weeks in. — as of 31 July 2026.
What were B.L.Kashyap & Sons Ltd's latest quarterly results?
B.L.Kashyap & Sons Ltd reported revenue of ₹364 Cr and a net loss of ₹13.0 Cr for the Mar 26 quarter. Earnings per share were ₹−0.56. The operating margin was 7.0%, 4.5 pp higher than a year earlier. — as of 31 July 2026.
What is B.L.Kashyap & Sons Ltd's revenue?
B.L.Kashyap & Sons Ltd reported revenue of ₹364 Cr in the Mar 26 quarter, +23.8% year on year. For the full FY26 fiscal year, revenue was ₹1,379 Cr (+19.5%). Over the last 10 years revenue compounded at 4.8% a year. — as of 31 July 2026.
What is B.L.Kashyap & Sons Ltd's profit?
B.L.Kashyap & Sons Ltd earned ₹−13.0 Cr of net profit in the Mar 26 quarter. Full-year FY26 profit was ₹2.0 Cr. The operating margin ran 7.0% in the latest quarter. — as of 31 July 2026.
What is B.L.Kashyap & Sons Ltd's market cap?
B.L.Kashyap & Sons Ltd's market capitalisation is ₹1,228 Cr at a share price of ₹54.5. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 31 July 2026.
What is B.L.Kashyap & Sons Ltd's P/E ratio?
B.L.Kashyap & Sons Ltd trades at a P/E of 90.2×, at the 76th percentile of its own 9-year range, against a long-run median of 33.4×. This is a comparison with the stock's own history, not a value call — as of 31 July 2026.
Does B.L.Kashyap & Sons Ltd pay a dividend?
No — B.L.Kashyap & Sons Ltd has recorded a dividend payout of 0% of profit in each of its last 13 reported fiscal years, so there is no payout history to quote. That is a reading of the filed annual statements, not an estimate. — as of 31 July 2026.
Is B.L.Kashyap & Sons Ltd overvalued?
On its own history, B.L.Kashyap & Sons Ltd looks expensive against its own history: its P/E of 90.2× sits at the 76th percentile of its 9-year range (long-run median 33.4×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 31 July 2026.
How is B.L.Kashyap & Sons Ltd performing?
B.L.Kashyap & Sons Ltd is building a base, 7 weeks in. Against the NIFTY 500 it has been behind on a trailing-13-week view for 6 weeks. This describes what the data did, not a rating. — as of 31 July 2026.
What stage is B.L.Kashyap & Sons Ltd in?
Mixed — no clean majority across the growth curves, ROCE holding at 13.0% — the per-curve reads carry the story. The read comes from the last 12 quarters of growth (revenue growth +23.8% latest, profit growth +1,100.0% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 31 July 2026.
Is B.L.Kashyap & Sons Ltd in an uptrend?
No — the price is building a base (week 7 of stage 1), trading −1.7% versus its 200-day average and at 34% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 31 July 2026.
Is B.L.Kashyap & Sons Ltd beating the market?
Not lately — on a trailing-13-week view B.L.Kashyap & Sons Ltd is currently behind the NIFTY 500 (6 weeks and counting; last ahead the week of 2026-06-25), the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.4 years the stock moved +272% against the NIFTY 500's +276% — behind the index over the full window. — as of 31 July 2026.
Will B.L.Kashyap & Sons Ltd's share price go up?
This page publishes no price forecast for B.L.Kashyap & Sons Ltd. What it measures instead: the share price is ₹54.5, the price is building a base 7 weeks in. Its P/E of 90.2× sits at the 76th percentile of its own 9-year range. — as of 31 July 2026.
Who owns B.L.Kashyap & Sons Ltd?
Promoters hold 61.7% of B.L.Kashyap & Sons Ltd, foreign institutions 0.3%, domestic institutions 0.2% and the public 37.9% (latest quarter). The biggest move on the register over the last two years: Foreign institutions cut 1.4 points over 8 quarters. — as of 31 July 2026.
Does B.L.Kashyap & Sons Ltd have too much debt?
It is moderate — B.L.Kashyap & Sons Ltd's debt-to-equity is 0.57, and operating profit covers the interest bill 2×. FY26 borrowings were ₹299 Cr against equity of ₹527 Cr. Read the returns on this page with that leverage in mind — as of 31 July 2026.
What is B.L.Kashyap & Sons Ltd's capex?
B.L.Kashyap & Sons Ltd spent ₹137 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹56.0 Cr, with ₹0.0 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 31 July 2026.
What is B.L.Kashyap & Sons Ltd's cash flow?
B.L.Kashyap & Sons Ltd generated ₹115 Cr of operating cash flow in FY26 and ₹59.0 Cr of free cash flow after ₹56.0 Cr of capital spending. Reported profit that year was ₹2.0 Cr, so operating cash ran ahead of profit. Cash-flow resolution for India is annual. — as of 31 July 2026.
Is B.L.Kashyap & Sons Ltd's profit real cash?
Yes — over the last 3 fiscal years, 329% of B.L.Kashyap & Sons Ltd's reported profit arrived as operating cash. In FY26, operating cash was ₹115 Cr against reported profit of ₹2.0 Cr. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 31 July 2026.
Where is B.L.Kashyap & Sons Ltd in its business cycle?
B.L.Kashyap & Sons Ltd's FY26 operating margin was 7.0%, against a 13-year band of 2.2%–10.0%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran 7.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 31 July 2026.
What could break the B.L.Kashyap & Sons Ltd story?
The sharpest disagreement: the price moved −27.5% in a year while annual EPS moved −94.3% — the difference is re-rating, and re-rating has to be repaid with earnings. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 31 July 2026.
Is B.L.Kashyap & Sons Ltd a stock worth studying right now?
This is not investment advice. The machine read: B.L.Kashyap & Sons Ltd's price has outrun its earnings. −27.5% in a year against EPS −94.3% — the market is paying now for delivery later. The sharpest open question: whether earnings grow into a price that has already moved. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 31 July 2026.